Detalles de la búsqueda
1.
Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.
Diabetes Obes Metab
; 26(6): 2412-2421, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38558508
Resultados
1 -
1
de 1
1
Próxima >
>>